Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion type Assertion NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_head.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_provenance.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion evidence source_evidence_literature NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_provenance.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion SIO_000772 21266922 NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_provenance.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion wasDerivedFrom befree-2016 NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_provenance.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion wasGeneratedBy ECO_0000203 NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_provenance.